Development and validation of a Sarcopenia Geriatric Scale (SARCO-GS): a new short scale for the screening of sarcopenia.
SARCO-GS
sarcopenia
scale
screening
validation
validity
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
03
2023
accepted:
04
07
2023
medline:
29
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Sarcopenia is a highly prevalent disease associated with adverse outcomes such as falls, disability, and death. The current international consensuses agree that muscle strength, muscle mass, and gait speed must be included in the definition. However, these proposed criteria require objective measurements that are not available for most populations. Since the timely identification of sarcopenia is a priority, several subjective screening scales have been developed; however, they have some limitations due to their low sensitivity. The objective of this work was to develop and validate SARCO-GS, a new short scale to screen sarcopenia that is affordable, easy, and accessible for all clinical care settings. The development of the SARCO-GS included four stages: (1) Review and analysis of documentary sources, (2) Contextualization of the theoretical model of sarcopenia, (3) Scale conformation, and (4) Reliability and validity analyses. SARCO-GS was validated in the FraDySMex study, which is a longitudinal cohort of community-dwelling adults. In the studied population (n=852), the average age was 68.9 years (SD 10.21) and 80.1% of the participants were women. SARCO-GS is a seven-item scale with an innovative structure that included five subjective questions (gait speed, muscular strength, muscle mass) and two measurements of muscular strength and muscle mass (Chair stand test and calf circumference). The results regarding criterion validity showed that the cut-off point ≥ 3 had good sensitivity (77.68%) versus the EWGSOP2 consensus, with an adequate Area Under the Receiver Operating Characteristic (AUC) (0.73), in addition to showing higher values of sensitivity and AUC than SARC-F and SARC-CalF using as reference the same consensus. Furthermore, SARCO-GS presented good predictive validity for functional dependence (HR=2.22, p=0.046) and acceptable correlation with other related measurements (construct validity). Regarding reliability, the scale showed acceptable internal reliability (correlation between items and total score: 0.50 to 0.70). After the validation analysis, the scale was adapted to English. The SARCO-GS is a novel scale to screen sarcopenia with high sensitivity, good construct, predictive validity, and internal reliability that may be useful for health professionals in different clinical settings and for clinical research.
Identifiants
pubmed: 37635955
doi: 10.3389/fendo.2023.1192236
pmc: PMC10450023
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1192236Informations de copyright
Copyright © 2023 Rosas-Carrasco, Omaña-Guzmán, García-González and Luna-López.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Med Dir Assoc. 2021 Sep;22(9):1864-1876.e16
pubmed: 34144049
J Am Med Dir Assoc. 2018 Mar;19(3):277.e1-277.e8
pubmed: 29477774
Int J Med Educ. 2011 Jun 27;2:53-55
pubmed: 28029643
Arch Gerontol Geriatr. 2021 Sep-Oct;96:104463
pubmed: 34218157
J Gerontol A Biol Sci Med Sci. 2014 May;69(5):547-58
pubmed: 24737557
Clin Nutr ESPEN. 2022 Apr;48:36-44
pubmed: 35331514
Clin Interv Aging. 2020 Dec 23;15:2415-2422
pubmed: 33380792
Rev Med Inst Mex Seguro Soc. 2011 Mar-Apr;49(2):153-62
pubmed: 21703142
Front Cardiovasc Med. 2021 Dec 09;8:743710
pubmed: 34957238
J Nutr Health Aging. 2018;22(9):1034-1038
pubmed: 30379299
Appl Neuropsychol. 2000;7(1):25-31
pubmed: 10800625
J Am Med Dir Assoc. 2016 Dec 1;17(12):1094-1098
pubmed: 27567463
J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2
pubmed: 32033882
Gerontology. 2022;68(4):361-376
pubmed: 34315158
J Am Geriatr Soc. 2020 Jul;68(7):1410-1418
pubmed: 32150289
J Cachexia Sarcopenia Muscle. 2021 Feb;12(1):30-38
pubmed: 33241660
Geriatr Gerontol Int. 2013 Oct;13(4):958-63
pubmed: 23452074
Bioengineering (Basel). 2020 Nov 06;7(4):
pubmed: 33172131
Front Med (Lausanne). 2021 Apr 13;8:655759
pubmed: 33928107
Front Med (Lausanne). 2021 Mar 15;8:617126
pubmed: 33791322
Aging Clin Exp Res. 2022 Oct;34(10):2449-2456
pubmed: 35918606
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
J Clin Epidemiol. 1993 Dec;46(12):1417-32
pubmed: 8263569
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Lancet. 2019 Jun 29;393(10191):2636-2646
pubmed: 31171417
Int J Geriatr Psychiatry. 2015 Mar;30(3):324-5
pubmed: 25631914
J Gerontol. 1994 Mar;49(2):M85-94
pubmed: 8126356
J Rehabil Med. 2019 Jun 18;51(6):456-463
pubmed: 31073618
Clin Nutr. 2020 Sep;39(9):2695-2701
pubmed: 31917049
J Am Med Dir Assoc. 2016 Dec 1;17(12):1136-1141
pubmed: 27650212
Clin Interv Aging. 2023 May 15;18:783-797
pubmed: 37215395
Salud Publica Mex. 2014 May-Jun;56(3):279-85
pubmed: 25272180
J Cachexia Sarcopenia Muscle. 2022 Oct;13(5):2331-2339
pubmed: 36017772
BMC Geriatr. 2023 Jan 9;23(1):13
pubmed: 36624367
PLoS One. 2017 Jan 17;12(1):e0169548
pubmed: 28095426
J Am Med Dir Assoc. 2013 Aug;14(8):531-2
pubmed: 23810110
Nurs Res. 2015 Mar-Apr;64(2):140-5
pubmed: 25738626
Arch Latinoam Nutr. 2007 Sep;57(3):255-65
pubmed: 18271404
Ageing Res Rev. 2022 Jun;78:101617
pubmed: 35378297
Anesth Analg. 2018 May;126(5):1763-1768
pubmed: 29481436
J Am Med Dir Assoc. 2016 Dec 1;17(12):1142-1146
pubmed: 27815111
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):86-99
pubmed: 34816624
J Nutr Health Aging. 2017;21(6):743-749
pubmed: 28537342
J Frailty Sarcopenia Falls. 2022 Dec 01;7(4):222-230
pubmed: 36531511